Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease

BMC Medicine

Volumn 15, Issue 1, 2017, Pages

  Struja, Tristan ^a   Kutz, Alexander ^a   Fischli, Stefan ^b   Meier, Christian ^c,d   Mueller, Beat ^a,c   Recher, Mike ^c,d   Schuetz, Philipp ^a,c  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Etiology; Graves' disease; Pathophysiology; Primary immunodeficiency; Review

Indexed keywords

ALEMTUZUMAB; B CELL ACTIVATING FACTOR; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR3; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; OSTEOPONTIN; PROTEIN BCL XL; SECONDARY LYMPHOID TISSUE CHEMOKINE; T LYMPHOCYTE RECEPTOR; THYROTROPIN; THYROTROPIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; APOPTOSIS; CASE CONTROL STUDY; CD25 GENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; DNA METHYLATION; DOWN REGULATION; GENE MUTATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME-WIDE ASSOCIATION STUDY; GRAVES DISEASE; HEPATITIS B; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PTPN22 GENE; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH2 CELL; YERSINIOSIS; ANIMAL; AUTOIMMUNITY; GENETICS; IMMUNE DEFICIENCY; IMMUNOLOGY;

ANIMALS; AUTOIMMUNITY; GRAVES DISEASE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES;

EID: 85029799632     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-017-0939-9     Document Type: Review

References (135)

1. Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood. 2002;99:2694-702.
2. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann Surg Oncol. 2013;20:660-7. doi: 10.1245/s10434-012-2606-x.
3. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14:174-80. doi: 10.1016/j.autrev.2014.10.016.
4. Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008;358:2594-605. doi: 10.1056/NEJMcp0801880.
5. Orgiazzi J. Thyroid autoimmunity. Presse Med. 2012;41:25. doi: 10.1016/j.lpm.2012.10.002.
6. Rabon S, Burton AM, White PC. Graves' disease in children: long term outcomes of medical therapy. Clin Endocrinol (Oxf). 2016;85(4):632-5. doi: 10.1111/cen.13099.
7. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930-4. doi: 10.1210/jcem.86.2.7242.
8. Brix TH, Christensen K, Holm NV, Harvald B, Hegedus L. A population-based study of Graves' disease in Danish twins. Clin Endocrinol (Oxf). 1998;48:397-400.
9. Brix TH, Hegedus L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf). 2012;76:457-64. doi: 10.1111/j.1365-2265.2011.04318.x.
10. Hall R, Stanbury JB. Familial studies of autoimmune thyroiditis. Clin Exp Immunol. 1967;2:719-25.
11. Prummel M, Strieder T, Wiersinga W. The environment and autoimmune thyroid diseases. Eur J Endocrinol. 2004;150:605-18. doi: 10.1530/eje.0.1500605.
12. McLeod DS, Cooper DS, Ladenson PW, Whiteman DC, Jordan SJ. Race/Ethnicity and the prevalence of thyrotoxicosis in young Americans. Thyroid. 2015;25:621-8. doi: 10.1089/thy.2014.0504.
13. Irvine WJ, Gray RS, Morris PJ, Ting A. Correlation of HLA and thyroid antibodies with clinical course of thyrotoxicosis treated with antithyroid drugs. Lancet. 1977;29;2(8044):898-900.
14. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu Rev Pathol Mech Dis. 2014;9:147-56. doi: 10.1146/annurev-pathol-012513-104713.
15. Lee HJ, Li CW, Hammerstad SS, Stefan M, Tomer Y. Immunogenetics of autoimmune thyroid diseases: A comprehensive review. J Autoimmun. 2015;64:82-90. doi: 10.1016/j.jaut.2015.07.009.
16. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and infection. N Engl J Med. 2014;370:2211-8. doi: 10.1056/NEJMra1213566.
17. Weetman AP. Immunity, thyroid function and pregnancy: molecular mechanisms. Nat Rev Endocrinol. 2010;6:311-8. doi: 10.1038/nrendo.2010.46.
18. Figueiredo AS, Schumacher A. The T helper type 17/regulatory T cell paradigm in pregnancy. Immunology. 2016;148:13-21. doi: 10.1111/imm.12595.
19. Ruocco MG, Chaouat G, Florez L, Bensussan A, Klatzmann D. Regulatory T-cells in pregnancy: historical perspective, state of the art, and burning questions. Front Immunol. 2014;5:389. doi: 10.3389/fimmu.2014.00389.
20. Aranha AA, Amer S, Reda ES, Broadley SA, Davoren PM. Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review. Endocr Pract. 2013;19:821-8. doi: 10.4158/EP13020.RA.
21. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30:99-105. doi: 10.1007/s10875-009-9327-3.
22. MacKay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697-710.
23. Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011;32:388-94. doi: 10.1016/j.it.2011.06.004.
24. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol. 2008;20:632-8. doi: 10.1016/j.coi.2008.09.001.
25. Vestergaard P. Smoking and thyroid disorders--a meta-analysis. Eur J Endocrinol. 2002;146:153-61.
26. Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79:145-51. doi: 10.1111/cen.12222.
27. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9. doi: 10.1038/nm.2305.
28. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med. 2004;10:1216-21. doi: 10.1038/nm1124.
29. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011;364:1920-31. doi: 10.1056/NEJMoa1012985.
30. Watt T, Cramon P, Bjorner JB, Bonnema SJ, Feldt-Rasmussen U, Gluud C, et al. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials. 2013;14:119. doi: 10.1186/1745-6215-14-119.
31. Duntas LH. The role of iodine and selenium in autoimmune thyroiditis. Horm Metab Res. 2015;47:721-6. doi: 10.1055/s-0035-1559631.
32. Goodnow CC. Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet. 2001;357:2115-21.
33. Sakaguchi N, Miyai K, Sakaguchi S. Ionizing radiation and autoimmunity. Induction of autoimmune disease in mice by high dose fractionated total lymphoid irradiation and its prevention by inoculating normal T cells. J Immunol. 1994;152:2586-95.
34. DeGroot LJ. Effects of irradiation on the thyroid gland. Endocrinol Metab Clin North Am. 1993;22:607-15.
35. Constine LS, McDougall IR. Radiation therapy for Hodgkin's disease followed by hypothyroidism and then Graves' hyperthyroidism. Clin Nucl Med. 1982;7:69-70.
36. Ostroumova E, Rozhko A, Hatch M, Furukawa K, Polyanskaya O, McConnell RJ, et al. Measures of thyroid function among Belarusian children and adolescents exposed to iodine-131 from the accident at the Chernobyl nuclear plant. Environ Health Perspect. 2013;121:865-71. doi: 10.1289/ehp.1205783.
37. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:693-702. doi: 10.1016/j.beem.2009.07.003.
38. Fry TJ, Connick E, Falloon J, Lederman MM, Liewehr DJ, Spritzler J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-90.
39. Wang XS, Li BZ, Hu LF, Wen PF, Zhang M, Pan HF, Ye DQ. Perspectives of the relationship between IL-7 and autoimmune diseases. Clin Rheumatol. 2013;32:1703-9. doi: 10.1007/s10067-013-2360-x.
40. Sheikh V, Porter BO, DerSimonian R, Kovacs SB, Thompson WL, Perez-Diez A, et al. Administration of interleukin-7 increases CD4 T cells in idiopathic CD4 lymphocytopenia. Blood. 2016;127:977-88. doi: 10.1182/blood-2015-05-645077.
41. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. 2005;174:3143-7.
42. Shenkman L, Bottone EJ. Antibodies to Yersinia enterocolitica in thyroid disease. Ann Intern Med. 1976;85:735-9.
43. Bech K, Hannover Larsen J, Mlholm Hansen J, Nerup J. Yersinia enterocolitica infection and thyroid disorders. Lancet. 1974;304:951-2. doi: 10.1016/S0140-6736(74)91152-0.
44. Bech K, Nerup J, Larsen JH. Yersinia enterocolitica infection and thyroid diseases. Acta Endocrinol (Copenh). 1977;84:87-92.
45. Hargreaves CE, Grasso M, Hampe CS, Stenkova A, Atkinson S, Joshua GW, et al. Yersinia enterocolitica provides the link between thyroid-stimulating antibodies and their germline counterparts in Graves' disease. J Immunol. 2013;190:5373-81. doi: 10.4049/jimmunol.1203412.
46. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43:661-72. doi: 10.1002/hep.21146.
47. Monzani F, Caraccio N, Dardano A, Ferrannini E. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med. 2004;3:199-210. doi: 10.1007/s10238-004-0026-3.
48. Martocchia A, Falaschi P. Amino acid sequence homologies between HCV polyprotein and thyroid antigens. Intern Emerg Med. 2007;2:65-7. doi: 10.1007/s11739-007-0018-x.
49. Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15:429-40. doi: 10.1038/nri3850.
50. Cattalini M, Galli J, Andreoli L, Olivieri I, Ariaudo G, Fredi M, et al. Exploring autoimmunity in a cohort of children with genetically confirmed Aicardi-Goutieres syndrome. J Clin Immunol. 2016;36:693-9. doi: 10.1007/s10875-016-0325-y.
51. Aversa T, Lombardo F, Valenzise M, Messina MF, Sferlazzas C, Salzano G, et al. Peculiarities of autoimmune thyroid diseases in children with Turner or Down syndrome: an overview. Ital J Pediatr. 2015;41:39. doi: 10.1186/s13052-015-0146-2.
52. de Luca F, Corrias A, Salerno M, Wasniewska M, Gastaldi R, Cassio A, et al. Peculiarities of Graves' disease in children and adolescents with Down's syndrome. Eur J Endocrinol. 2010;162:591-5. doi: 10.1530/EJE-09-0751.
53. Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, et al. Trisomy 21 consistently activates the interferon response. Elife. 2016;5, e16220. doi: 10.7554/eLife.16220.
54. Ploski R, Szymanski K, Bednarczuk T. The genetic basis of graves' disease. Curr Genomics. 2011;12:542-63. doi: 10.2174/138920211798120772.
55. Tomer Y, Ban Y, Concepcion E, Barbesino G, Villanueva R, Greenberg DA, Davies TF. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am J Hum Genet. 2003;73:736-47. doi: 10.1086/378588.
56. Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc Natl Acad Sci U S A. 2003;100:15119-24. doi: 10.1073/pnas.2434175100.
57. Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, et al. Employing a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective. J Biol Chem. 2009;284:34231-43. doi: 10.1074/jbc.M109.041574.
58. Kanistras I, Hatzioannou A, Lymberi P. A novel pathogenic peptide of thyroglobulin (2208-2227) induces autoreactive T-cell and B-cell responses in both high and low responder mouse strains. Immunology. 2014;142:300-6. doi: 10.1111/imm.12254.
59. Gokturk B, Keles S, Kirac M, Artac H, Tokgoz H, Guner SN, et al. CD3G gene defects in familial autoimmune thyroiditis. Scand J Immunol. 2014;80:354-61. doi: 10.1111/sji.12200.
60. Marino M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the etiology of Graves' disease. J Endocrinol Invest. 2015;38:283-94. doi: 10.1007/s40618-014-0214-2.
61. Colobran R, Gimenez-Barcons M, Marin-Sanchez A, Porta-Pardo E, Pujol-Borrell R. AIRE genetic variants and predisposition to polygenic autoimmune disease: The case of Graves' disease and a systematic literature review. Hum Immunol. 2016;77:643-51. doi: 10.1016/j.humimm.2016.06.002.
62. Bona G, Defranco S, Chiocchetti A, Indelicato M, Biava A, Difranco D, et al. Defective function of Fas in T cells from paediatric patients with autoimmune thyroid diseases. Clin Exp Immunol. 2003;133:430-7.
63. Fountoulakis S, Vartholomatos G, Kolaitis N, Frillingos S, Philippou G, Tsatsoulis A. Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis. Eur J Endocrinol. 2008;158:853-9. doi: 10.1530/EJE-08-0092.
64. Salmaso C, Bagnasco M, Pesce G, Montagna P, Brizzolara R, Altrinetti V, et al. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves' disease. Ann N Y Acad Sci. 2002;966:496-501.
65. Bacchetta R, Barzaghi F, Roncarolo MG. From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. Ann N Y Acad Sci. 2016. doi: 10.1111/nyas.13011.
66. Pellegrini FP, Marinoni M, Frangione V, Tedeschi A, Gandini V, Ciglia F, et al. Down syndrome, autoimmunity and T regulatory cells. Clin Exp Immunol. 2012;169:238-43. doi: 10.1111/j.1365-2249.2012.04610.x.
67. Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482-7. doi: 10.1016/j.jaci.2006.10.007.
68. Mao C, Wang S, Xiao Y, Xu J, Jiang Q, Jin M, et al. Impairment of regulatory capacity of CD4 + CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves' disease. J Immunol. 2011;186:4734-43. doi: 10.4049/jimmunol.0904135.
69. Chistiakov DA, Chistiakova EI, Voronova NV, Turakulov RI, Savost'anov KV. A variant of the Il2ra / Cd25 gene predisposing to graves' disease is associated with increased levels of soluble interleukin-2 receptor. Scand J Immunol. 2011;74:496-501. doi: 10.1111/j.1365-3083.2011.02608.x.
70. Song ZY, Liu W, Xue LQ, Pan CM, Wang HN, Gu ZH, et al. Dense mapping of IL2RA shows no association with Graves' disease in Chinese Han population. Clin Endocrinol (Oxf). 2013;79:267-74. doi: 10.1111/cen.12115.
71. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332:600-3. doi: 10.1126/science.1202947.
72. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res. 2016;22:1856-64. doi: 10.1158/1078-0432.CCR-15-1849.
73. Corsello SM, Barnabei A, Marchetti P, de Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98:1361-75. doi: 10.1210/jc.2012-4075.
74. Narita T, Oiso N, Taketomo Y, Okahashi K, Yamauchi K, Sato M, et al. Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. J Dermatol. 2016;43:210-4. doi: 10.1111/1346-8138.13028.
75. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20:1410-6. doi: 10.1038/nm.3746.
76. Wickman G, Julian L, Olson MF. How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ. 2012;19:735-42. doi: 10.1038/cdd.2012.25.
77. van Schaarenburg RA, Schejbel L, Truedsson L, Topaloglu R, Al-Mayouf SM, Riordan A, et al. Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. J Autoimmun. 2015;62:39-44. doi: 10.1016/j.jaut.2015.06.002.
78. Hanayama R, Tanaka M, Miyasaka K, Aozasa K, Koike M, Uchiyama Y, Nagata S. Autoimmune disease and impaired uptake of apoptotic cells in MFG-E8-deficient mice. Science. 2004;304:1147-50. doi: 10.1126/science.1094359.
79. Potlukova E, Jiskra J, Limanova Z, Kralikova P, Smutek D, Mareckova H, et al. Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clin Exp Immunol. 2008;153:96-101. doi: 10.1111/j.1365-2249.2008.03670.x.
80. Mobarrez F, Abraham-Nordling M, Aguilera-Gatica K, Friberg I, Antovic A, Pisetsky DS, et al. The expression of microvesicles in the blood of patients with Graves' disease and its relationship to treatment. Clin Endocrinol (Oxf). 2016;84:729-35. doi: 10.1111/cen.12872.
81. Weetman AP. Grave's disease 1835-2002. Horm Res. 2003;59 Suppl 1:114-8.
82. Kristensen B. Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls. Dan Med J. 2016;63(2):1-27.
83. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. Clin Endocrinol (Oxf). 2008;69:311-7. doi: 10.1111/j.1365-2265.2008.03192.x.
84. Rees SB, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev. 1988;9:106-21. doi: 10.1210/edrv-9-1-106.
85. Ruffilli I, Ferrari SM, Colaci M, Ferri C, Fallahi P, Antonelli A. IP-10 in autoimmune thyroiditis. Horm Metab Res. 2014;46:597-602. doi: 10.1055/s-0034-1382053.
86. Leporati P, Groppelli G, Zerbini F, Rotondi M, Chiovato L. Etiopathogenesis of Basedow's disease. Trends and current aspects. Nuklearmedizin. 2015;54:204-10. doi: 10.3413/Nukmed-0739-15-04.
87. McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014;35:59-105. doi: 10.1210/er.2013-1055.
88. McLachlan SM. Guest Editorial: Graves' Disease: The TH1/TH2 Paradigm versus the "Hygiene" Hypothesis and Defective Immune Regulation. Thyroid. 2003;13:127-8. doi: 10.1046/j.1365-2702.2003.00768.x.
89. Stassi G, de Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol. 2002;2:195-204. doi: 10.1038/nri750.
90. Reza S, Shaukat A, Arain TM, Riaz QS, Mahmud M. Expression of osteopontin in patients with thyroid dysfunction. PLoS One. 2013;8, e56533. doi: 10.1371/journal.pone.0056533.
91. Xu L, Ma X, Wang Y, Li X, Qi Y, Cui B, et al. The expression and pathophysiological role of osteopontin in Graves' disease. J Clin Endocrinol Metab. 2011;96:E1866-70. doi: 10.1210/jc.2011-1339.
92. Qi Y, Li X, Ma X, Xu L, Zhang X, Jiang X, et al. The role of osteopontin in the induction of the CD40 ligand in Graves' disease. Clin Endocrinol (Oxf). 2014;80:128-34. doi: 10.1111/cen.12229.
93. Li X, Qi Y, Ma X, Huang F, Guo H, Jiang X, et al. Chemokine (C-C motif) ligand 20, a potential biomarker for Graves' disease, is regulated by osteopontin. PLoS One. 2013;8, e64277. doi: 10.1371/journal.pone.0064277.
94. Qi Y, Li X, Zhang Q, Huang F, Lin D, Zhou Y, et al. Increased chemokine (C-C motif) ligand 21 expression and its correlation with osteopontin in Graves' disease. Endocrine. 2015;50:123-9. doi: 10.1007/s12020-015-0552-7.
95. Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. Autoimmun Rev. 2014;13:163-77. doi: 10.1016/j.autrev.2013.10.005.
96. Mohammadi J, Ramanujam R, Jarefors S, Rezaei N, Aghamohammadi A, Gregersen PK, Hammarstrom L. IgA deficiency and the MHC: assessment of relative risk and microheterogeneity within the HLA A1 B8, DR3 (8.1) haplotype. J Clin Immunol. 2010;30:138-43. doi: 10.1007/s10875-009-9336-2.
97. Bronson PG, Chang D, Bhangale T, Seldin MF, Ortmann W, Ferreira RC, et al. Common variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A are associated with selective IgA deficiency. Nat Genet. 2016. doi: 10.1038/ng.3675.
98. Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015;181:191-206. doi: 10.1111/cei.12641.
99. Takeshima K, Inaba H, Furukawa Y, Nishi M, Yamaoka H, Miyamoto W, et al. Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications. Thyroid. 2014;24:736-43. doi: 10.1089/thy.2013.0448.
100. Khosroshahi A, Cheryk LA, Carruthers MN, Edwards JA, Bloch DB, Stone JH. Brief Report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol. 2014;66:213-7. doi: 10.1002/art.38193.
101. Nishihara E, Hirokawa M, Ito M, Fukata S, Nakamura H, Amino N, Miyauchi A. Graves' disease patients with persistent hyperthyroidism and diffuse lymphoplasmacytic infiltration in the thyroid show no histopathological compatibility with IgG4-related disease. PLoS One. 2015;10, e0134143. doi: 10.1371/journal.pone.0134143.
102. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192:129-35.
103. Gilbert JA, Kalled SL, Moorhead J, Hess DM, Rennert P, Li Z, et al. Treatment of autoimmune hyperthyroidism in a murine model of Graves' disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology. 2006;147:4561-8. doi: 10.1210/en.2006-0507.
104. Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, et al. BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010;9:165-9. doi: 10.1016/j.autrev.2009.07.005.
105. Vannucchi G, Covelli D, Curro N, Dazzi D, Maffini A, Campi I, et al. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy. J Clin Endocrinol Metab. 2012;97:E755-9. doi: 10.1210/jc.2011-2614.
106. Lin JD, Yang SF, Wang YH, Fang WF, Lin YC, Lin YF, et al. Analysis of Associations of human BAFF gene polymorphisms with autoimmune thyroid diseases. PLoS One. 2016;11, e0154436. doi: 10.1371/journal.pone.0154436.
107. Pieper K, Rizzi M, Speletas M, Smulski CR, Sic H, Kraus H, et al. A common single nucleotide polymorphism impairs B-cell activating factor receptor's multimerization, contributing to common variable immunodeficiency. J Allergy Clin Immunol. 2014;133:1222-5. doi: 10.1016/j.jaci.2013.11.021.
108. Qamar N, Fuleihan RL. The hyper IgM syndromes. Clin Rev Allergy Immunol. 2014;46:120-30. doi: 10.1007/s12016-013-8378-7.
109. Rodriguez-Cortez VC, Del P-ML, Rodriguez-Ubreva J, Ciudad L, Gomez-Cabrero D, Company C, et al. Monozygotic twins discordant for common variable immunodeficiency reveal impaired DNA demethylation during naive-to-memory B-cell transition. Nat Commun. 2015;6:7335. doi: 10.1038/ncomms8335.
110. Wood A, Shilatifard A. Posttranslational modifications of histones by methylation. Adv Protein Chem. 2004;67:201-22. doi: 10.1016/S0065-3233(04)67008-2.
111. Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB, et al. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci U S A. 2014;111:12562-7. doi: 10.1073/pnas.1408821111.
112. Savino W. The thymus is a common target organ in infectious diseases. PLoS Pathog. 2006;2, e62. doi: 10.1371/journal.ppat.0020062.
113. Gupta B, Hawkins RD. Epigenomics of autoimmune diseases. Immunol Cell Biol. 2015;93:271-6. doi: 10.1038/icb.2015.18.
114. Aslani S, Mahmoudi M, Karami J, Jamshidi AR, Malekshahi Z, Nicknam MH. Epigenetic alterations underlying autoimmune diseases. Autoimmunity. 2016;49:69-83. doi: 10.3109/08916934.2015.1134511.
115. Wang Z, Fan X, Zhang R, Lin Z, Lu T, Bai X, et al. Integrative analysis of mRNA and miRNA array data reveals the suppression of retinoic acid pathway in regulatory T cells of Graves' disease. J Clin Endocrinol Metab. 2014;99:7. doi: 10.1210/jc.2014-1883.
116. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007;76:75-100. doi: 10.1146/annurev.biochem.76.052705.162114.
117. Yan N, Zhou JZ, Zhang JA, Cai T, Zhang W, Wang Y, et al. Histone hypoacetylation and increased histone deacetylases in peripheral blood mononuclear cells from patients with Graves' disease. Mol Cell Endocrinol. 2015;414:143-7. doi: 10.1016/j.mce.2015.05.037.
118. Yin X, Latif R, Tomer Y, Davies TF. Thyroid epigenetics: X chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci. 2007;1110:193-200. doi: 10.1196/annals.1423.021.
119. Limbach M, Saare M, Tserel L, Kisand K, Eglit T, Sauer S, et al. Epigenetic profiling in CD4+ and CD8+ T cells from Graves' disease patients reveals changes in genes associated with T cell receptor signaling. J Autoimmun. 2016;67:46-56. doi: 10.1016/j.jaut.2015.09.006.
120. Canas CA, Canas F, Bonilla-Abadia F, Ospina FE, Tobon GJ. Epigenetics changes associated to environmental triggers in autoimmunity. Autoimmunity. 2016;49:1-11. doi: 10.3109/08916934.2015.1086996.
121. Cai TT, Muhali FS, Song RH, Qin Q, Wang X, Shi LF, et al. Genome-wide DNA methylation analysis in Graves' disease. Genomics. 2015;105:204-10. doi: 10.1016/j.ygeno.2015.01.001.
122. Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C, Muller B, Schuetz P. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol. 2017;176(1):87-97. doi: 10.1530/EJE-16-0725.
123. DeGroot LJ. Diagnosis and treatment of Graves' disease. In: de Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc; 2000.
124. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352:905-17. doi: 10.1056/NEJMra042972.
125. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2010;1, CD003420. doi: 10.1002/14651858.CD003420.pub4.
126. Cappellano G, Orilieri E, Woldetsadik AD, Boggio E, Soluri MF, Comi C, et al. Anti-cytokine autoantibodies in autoimmune diseases. Am J Clin Exp Immunol. 2012;1:136-46.
127. Piccoli L, Campo I, Fregni CS, Rodriguez BMF, Minola A, Sallusto F, et al. Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat Commun. 2015;6:7375. doi: 10.1038/ncomms8375.
128. Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T, et al. Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS One. 2014;9, e113465. doi: 10.1371/journal.pone.0113465.
129. Struja T, Guebelin L, Kutz A, Fehlberg H, Mueller B, Schuetz P. Does immunosuppressive therapy improve outcomes in Graves' disease? A systematic review and meta-analysis. Thyroid. 2016;26:634-40. doi: 10.1089/thy.2015.0647.
130. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94:2708-16. doi: 10.1210/jc.2009-0376.
131. Ganesan A. Multitarget drugs: an epigenetic epiphany. ChemMedChem. 2016;11(12):1227-41. doi: 10.1002/cmdc.201500394.
132. Baker Jr J, Lukes YG, Burman KD. Production, isolation, and characterization of rabbit anti-idiotypic antibodies directed against human antithyrotrophin receptor antibodies. J Clin Invest. 1984;74:488-95. doi: 10.1172/JCI111446.
133. Kahaly G, Pitz S, Muller-Forell W, Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol. 1996;106:197-202.
134. Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi P. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid. 1997;7:579-85. doi: 10.1089/thy.1997.7.579.
135. Davies TF, Latif R. Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies. Expert Opin Ther Targets. 2015;19:835-47. doi: 10.1517/14728222.2015.1018181.